The tablet almost nobody keeps taking

By Nirbhay Agarwal · 19 August 2026 · 6 min read

In 2008 a group of researchers did something simple and slightly brutal. They took prescription records for the seven common chronic conditions compared above, applied one consistent definition of adherence to all of them, and asked how many people were still reliably taking their medication a year after starting.

Gout was last. Not marginally last — the six other conditions clustered between 51% and 72%, and gout sat fourteen points below the next worst. A later systematic review found adherence to urate-lowering therapy ranging from 10% to 46% across studies, which is to say: the 2008 result was not a fluke of one dataset.

The 2020 American College of Rheumatology guideline states it flatly in its opening paragraphs. Adherence to urate-lowering therapy, it says, “is the lowest adherence among treatments for 7 common chronic medical conditions.”

This is a strange thing to be true. Gout is one of the few forms of inflammatory arthritis that is genuinely, mechanically curable — the deposits can be dissolved and made to disappear. The main drug is old, cheap and generic. And it is the medication people are least likely to keep taking.

Why is allopurinol so hard to keep taking?

It is tempting to read a number like 36.8% as a statement about the people. It is more useful to read it as a statement about the design of the problem, because four things about gout treatment work against continuing it, and they compound.

The drug does nothing you can feel. Allopurinol produces no sensation. There is no relief when you take it and no immediate consequence when you skip it. Every day it works perfectly feels exactly like every day you forget. Blood pressure tablets share this problem, which is why their adherence is also imperfect — but with gout there is an additional twist.

The disease disappears between flares. For most of the year there is no evidence you have gout at all. The joint is fine. Nothing hurts. In the gap between attacks, the tablet is treating something you have no way to perceive, and the natural inference — this seems to have gone away — is wrong in a way nothing in your experience corrects.

Early treatment makes things worse, and the mechanism is invisible. This is the one that does the real damage. Starting urate-lowering therapy commonly increases flares for the first months, because deposits destabilise as they begin to dissolve. Judged by symptoms, a treatment that has started working is indistinguishable from a treatment that is making you ill. That is the subject of why gout gets worse before it gets better, and it is the single most predictable moment for someone to stop.

And the flare, when it comes, gets treated as the event. Attacks are dramatic and the attack has its own medication. It is easy for the daily preventive tablet to become mentally filed as background noise while colchicine or an anti-inflammatory becomes “the gout medication” — treating the fire and quietly discontinuing the fireproofing. The two do completely different jobs, which is worth having straight before you need either: what the guidelines say to do when a flare starts.

None of these are failures of willpower. They are what happens when a silent disease is treated with a silent drug that temporarily makes you feel worse.

What happens if you don’t take allopurinol regularly?

The most informative data on this comes from NOR-Gout, a Norwegian study that followed people for five years after they started urate-lowering therapy, then compared outcomes across how consistently they had taken it.

Among the 163 people who completed five years, comparing the least adherent quarter to the most adherent:

• Flares in the final year of follow-up: 33.3% versus 9.4%
• Reaching the serum urate target at five years: 45.2% versus 87.5%

Roughly a threefold difference in flares, and nearly double the chance of being at target. This is not a subtle signal, and it is worth being clear about the direction of causation: the point of the tablet is to hold your urate under the line, and if it is not being taken, it does not.

Can you stop urate-lowering therapy once the flares stop?

A reasonable question, and one the guideline takes seriously: if the deposits dissolve and the flares stop, why keep going?

The ACR conditionally recommends continuing urate-lowering therapy indefinitely rather than stopping. It flags this as very low certainty evidence, which is honest — the evidence is one case series rather than a trial. But that series is striking. Among people in clinical remission whose treatment was withdrawn, only 13% (27 of 211) went the next five years without a flare. Those whose urate rose highest after stopping flared most.

The snow analogy explains why. Clearing the roof does not change the weather. Your kidneys handle urate the way they always did; what changed was that a drug was offsetting it. Remove the drug and the level returns to where your physiology puts it, and it starts snowing again — silently, for however long it takes to build back up.

What actually helps people stay on it?

The guideline’s own answer is structural rather than motivational. It conditionally recommends an augmented model of dose management — one that “includes patient education, shared decision-making, and treat-to-target protocol,” potentially delivered by nurses or pharmacists rather than physicians. Trials of that model showed better adherence, better urate control and better patient satisfaction than usual care.

Strip out the health-system language and the active ingredients are: someone explains what the drug is doing, the target is made explicit, and the number gets checked on a schedule rather than when someone remembers.

Two of those three you can do without waiting for anyone.

Know your number and your target. “I am on allopurinol” is not a treatment status. “My last urate was 6.4 mg/dL and we are aiming under 6.0 mg/dL” is. The first cannot tell you whether anything is working; the second is the whole readout. If it has been more than six months since anyone measured it, that is worth an appointment on its own — see when gout treatment stalls, check the dose.

Keep the sequence, not the impression. One urate value is nearly meaningless. Four values over two years, with the dose next to each, is a picture of whether the treatment is working — and it converts your side of the consultation from recollection into evidence.

Expect the bad stretch, and mark it on the calendar. The flare-prone months at the start of treatment are anticipated in the guideline, which is why it strongly recommends anti-inflammatory cover for three to six months when starting. Knowing that period is finite, and that it is a sign of deposits breaking up rather than treatment failing, is most of what gets people through it.

The 36.8% figure is not really a fact about patients. It is a fact about how badly this disease is explained. A tablet whose purpose you understand, aimed at a number you can see, is a substantially easier thing to keep taking than a tablet that seems to do nothing while you feel worse.

Gout Journal is written by someone who lives with gout, not by a clinician. This article is general information, not medical advice — never start, stop or change a medication without talking to your own doctor.